ibritumomab tiuxetan + bortezomib

A combination regimen of the radioimmunotherapy ibritumomab tiuxetan and the proteasome inhibitor bortezomib, investigated primarily for B-cell non-Hodgkin lymphoma. Ibritumomab tiuxetan is an anti-CD20 monoclonal antibody conjugated via the chelator tiuxetan to a radionuclide (commonly yttrium-90 for therapy; indium-111 for imaging), delivering targeted radiation to CD20-positive B cells and inducing cell death through beta emission and immune effector functions. Bortezomib is a reversible inhibitor of the 26S proteasome that disrupts protein degradation, leading to cell cycle arrest and apoptosis in malignant cells. The combination is intended to enhance antitumor activity by depleting CD20-positive B cells with radiotherapy while simultaneously sensitizing lymphoma cells to cytotoxic stress through proteasome inhibition.

Other names

Zevalin + bortezomibibritumomab tiuxetan radiolabeled + bortezomib